More Telix Pharmaceuticals Limited news
Telix Pharmaceuticals LimitedASX: TLX

Telix and GenesisCare Commence Prostate Cancer Study

Aug 7, 2019 at 10:45 PM EDT · Issued by Telix Pharmaceuticals Limited

Filed with ASX · Aug 7, 2019 at 10:45 PM EDT

On 6ix: 6ix.com/news/telix-and-genesiscare-commence-prostate-cancer-study

Watch Telix Pharmaceuticals' latest call↗Telix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call · Replay · Aug 20Read the transcript of Telix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call↗

Telix Pharmaceuticals Ltd has released a press release.

View Attachment

6ix hasn’t read this filing yet.

Telix Pharmaceuticals Limited on 6ix

Earlier from Telix Pharmaceuticals

  • Telix and Merck Group Combination Therapy CollaborationJul 31, 2019
  • Sales Note to Accompany June 2019 Quarter Appendix 4CJul 30, 2019
  • Appendix 4C - June 2019 QuarterJul 30, 2019
  • Telix Receives $9.3m R&D Tax RefundJul 18, 2019
  • Investor PresentationJul 16, 2019

Later from Telix Pharmaceuticals

  • Telix Pharmaceuticals announces results of successful SPPAug 19, 2019
  • First Australian Patient Dosed in ZIRCON Phase III TrialAug 20, 2019
  • Appendix 4D and Financial Report for half-year to 30 June 19Aug 22, 2019
  • FDA Pre-NDA Meeting Outcomes - TLX591-CDx illumetAug 27, 2019
  • Telix to Acquire European Production FacilityOct 2, 2019
All Telix Pharmaceuticals news releases↗

Follow Telix Pharmaceuticals into a list and get an email when it puts out news.

Follow Telix Pharmaceuticals
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer